CN1678322A - (4-(2-氟苯基)-6-甲基-2-(1-哌嗪基)噻吩并[2,3-d]嘧啶的新治疗用途 - Google Patents
(4-(2-氟苯基)-6-甲基-2-(1-哌嗪基)噻吩并[2,3-d]嘧啶的新治疗用途 Download PDFInfo
- Publication number
- CN1678322A CN1678322A CNA03820617XA CN03820617A CN1678322A CN 1678322 A CN1678322 A CN 1678322A CN A03820617X A CNA03820617X A CN A03820617XA CN 03820617 A CN03820617 A CN 03820617A CN 1678322 A CN1678322 A CN 1678322A
- Authority
- CN
- China
- Prior art keywords
- thieno
- piperazinyl
- fluorophenyl
- pyrimidine
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
(4-(2-氟苯基)-6-甲基-2-(1-哌嗪基)噻吩并[2,3-D]嘧啶或其盐在纤维肌痛、肥胖、体重增加和其它状况的治疗中具有价值。
Description
发明领域
本发明涉及一种已知化合物的新用途。
发明背景
近来开发了许多非三环类抗抑郁剂,它们减少了三环类抗抑郁剂所具有的特征,即心血管和抗胆碱能倾向。这些药剂包括抑制5-羟色胺和或去甲肾上腺素的摄取的那些。关于这些药剂已提出了许多用途,包括治疗肥胖和体重增加、帕金森氏病、癫痫、精神分裂症、强迫观念与行为障碍、物质滥用和药物成瘾、经前期综合征、进食障碍和偏头痛以及用于鼓励吸烟停止。并非所有非三环类抗抑郁剂在所有疾病/状况中起作用以及对每种疾病/状况来说,去甲肾上腺素摄取抑制相对5-羟色胺摄取抑制的优点不清楚。
(4-(2-氟苯基)-6-甲基-2-(1-哌嗪基)噻吩并[2,3-D]嘧啶一水化物盐酸化物是已知的(见US-A-4695568)。它具有5-羟色胺和去甲肾上腺素再摄取阻断性质,但也具有重要的5HT-3受体阻断活性,它被期望以一种不可预知的方式在体内修改所述化合物的药理学作用。最近在WO 02/094249、WO 03/063873和PCT/GB03/02974中分别描述了这种化合物在治疗疼痛,泌尿性障碍,和机能性肠障碍中的实用(在本案要求的第一优先权日期之前没有一篇被公开)。
发明概述
令人惊奇地,已发现上面所鉴别的已知化合物(本文称为MCI-225)在肥胖和体重增加、帕金森氏病、癫痫、精神分裂症、强迫观念与行为障碍、物质滥用、吸烟(鼓励停止)、经前期综合征、进食障碍、偏头痛,中风恢复、纤维肌痛(fibromyalgia)、疲劳、恶心、呕吐和包括由癌症化学疗法和放射疗法所产生的呕吐的治疗中能具有有价值的活性。它的5-羟色胺和去甲肾上腺素再摄取阻断与5HT-3受体阻断的结合以前没有被清楚地鉴别为造成这些活性的原因。将理解,可以使用任何适合形式的活性成分,例如另一种盐形式,或前药或活性代谢物。
优选实施方案的描述
以本发明,可以治疗,例如控制或预防上文概括的疾病/状况。本发明的特定实施方案是用于纤维肌痛,一种以疲劳和分布广的肌肉、韧带和腱中疼痛为特征的慢性状况的治疗。这种状况以前以其它名称,例如纤维织炎、慢性肌肉疼痛综合征、精神性风湿病和紧张肌痛相称。
本发明的另一种实施方案在于治疗肥胖或体重增加的方法。这意思是指减少体重、减轻超重、减轻增加的体重,或减轻肥胖;它们全部通常是由大量的食物消耗引起的。
本发明的还另一种实施方案在于治疗帕金森氏病的方法。这意思是指减轻帕金森氏病的症状,该症状包括,但不限于,人缓慢地增加的有目的运动中的无能、震颤、运动过慢、强直,和姿势失调。
本发明的还另一种实施方案在于治疗疲劳的方法,包括与由所述疾病引起的癌症患者有关的疲劳和/或其治疗,患包括慢性肝炎C的慢性肝疾病患者中的疲劳以及患慢性疲劳综合征患者中的疲劳。
还一种实施方案在于治疗强迫观念与行为障碍、物质滥用、经前期综合征、进食障碍和偏头痛。本文以与它们在本领域被接受的含义一致的方式使用这些术语。参见,例如Diagnostic and StatisticalManual of Mental Disorders 4th Ed,American PsychiatricAssociation(1997)。
本文可结合本发明涉及的障碍使用的术语“治疗或预防的方法”、“治疗的方法”和“预防的方法”。这些术语意思是指与这些障碍有关的症状和/或影响的改善、预防或减轻,并被包括在本发明的范围内。
为本发明的目的,可以任何适合的方式与常规稀释剂或载体一起配制活性化合物。优选通过口服途径施用活性化合物;其它适合的给药途径包括舌下/颊的、透皮的、肌内的、鼻内的、直肠的、胃肠外的、皮下的、肺的和局部的。活性剂的有效剂量将取决于主诉的属性和程度,患者的年龄和状况以及对本领域技术人员来说已知的其它因素。典型的日剂量可以是0.1mg至5g。
含有活性成分的药物组合物可以呈舌下片剂或贴剂的形式。经口使用的适合的组合物包括片剂、锭剂(troches)、糖锭(lozenges)、水性或油性混悬液,可分散的粉剂或颗粒、乳剂、硬或软胶囊、糖浆和酏剂。适合的添加剂包括甜味剂、调味剂、着色剂和防腐剂。片剂含有与无毒的药学上可接受的赋形剂混合的活性成分,所述赋形剂例如惰性稀释剂例如碳酸钙、碳酸钠、乳糖、磷酸钙或磷酸钠;造粒和崩解剂,例如玉米淀粉、或海藻酸;粘合剂,例如淀粉、明胶或阿拉伯胶,和润滑剂,例如硬脂酸镁、硬脂酸或滑石粉。所述片剂可以是无包衣的或可通过已知技术将它们包衣以延迟在胃肠道中的崩解和吸收,并由此在长时期内提供持续作用。例如,可以使用一种时间延迟材料如单硬脂酸甘油酯或二硬脂酸甘油酯。还可以将它们包衣,以形成渗透性治疗片剂用于控释。硬明胶胶囊可以包含惰性固体稀释剂,例如碳酸钙、磷酸钙或白陶土;软明胶胶囊可以包含水或油介质,例如花生油、液体石蜡或橄榄油。
作为实施例给出下面的方法以举例说明如何证实MCI-225的有益作用。上文提及的三篇最近的PCT出版物/申请中提供的证据,也可能是有关的。
肥胖和体重增加的治疗
在成年雌性肥胖Zucker大鼠中评价了MCI-225 32天时间。每天单独用赋形剂给予6只动物的对照组,而6只体重匹配的动物的第二组接受每天一次以30mg/kg口服给予的MCI-225。食物自由可得,除第0、7、14、21、28和32以外,这几天在上午7.30从动物拿走食物,并在拿走食物后两小时内称量动物。测量动物体重后供给食物。通过MCI-225治疗的动物更低的体重证实有益作用。
物质滥用/药物成瘾的治疗
在乙醇喜欢性(alcohol-preferring)大鼠中测定了MCI-225的作用。因为它们的饮用模式,这些动物似乎代表人乙醇中毒状况的有效模型(McBride等,1990,Alcohol 7:199-205,Lankford等,1991,Pharmacol.Biochem.Behav.,8:293-299)。在最大优选的乙醇浓度稳定4天后,给予MCI-225 30mg/kg/天口服或赋形剂连续4天。通过以绝对g/kg和/或乙醇与总流体摄取的比表示的乙醇摄取的减少证实MCI-225治疗的有益作用。
吸烟的停止
在大鼠使用听觉惊跳反射的尼古丁停药模型中研究了MCI-225的作用(参见,例如Helton等,1997,Neuropharmacology 36(11-12):1511-1516)。通过渗透小泵皮下给予尼古丁(6mg/kg/天)12天。12天后,撤去泵,让动物经历自发的停药。长期尼古丁暴露的停止导致停药后4天的增加的惊跳反应(感觉运动反应性)。通过尼古丁停药后增强的听觉惊跳反应的衰减证实MCI-225治疗,例如尼古丁停药后30mg/kg/天的益处。
中风的治疗
在大鼠瞬时大脑中动脉阻塞模型中研究了MCI-225的作用(参见Chen等,1999,J.Neurol.Sci.171(1):24-30)。特别是,研究了对一批机能度量的作用,包括转杆(rotarod)、粘附支持(adhesive-backed)体感和神经学评分。通过与赋形剂处理的动物比较,局部缺血后测量的机能评分的一种或多种的改进,证实用例如在阻塞发生后2小时给予的30mg/kg MCI-225治疗的有益作用。
恶心/呕吐的治疗
在鼬(ferret)中研究了MCI-225对顺铂诱导的呕吐的作用(参见Florczyk等,1982,Cancer Treat.Rep.66(1):187-189)。通过与对照动物比较,呕吐反应的减少证实用在顺铂给药前1小时口服给予的30mg/kg MCI-225治疗的有益作用。抗顺铂的功效预测抗放射引起的恶心/呕吐的功效。通过在鼬模型中使用包括阿朴吗啡的其它催吐剂(emetogens)可证实MCI-225更广谱的止吐活性。
Claims (15)
1.(4-(2-氟苯基)-6-甲基-2-(1-哌嗪基)噻吩并[2,3-D]嘧啶或其盐在制备用于治疗纤维肌痛的药物中的用途。
2.(4-(2-氟苯基)-6-甲基-2-(1-哌嗪基)噻吩并[2,3-D]嘧啶或其盐在制备用于治疗肥胖和体重增加的药物中的用途。
3.(4-(2-氟苯基)-6-甲基-2-(1-哌嗪基)噻吩并[2,3-D]嘧啶或其盐在制备用于治疗物质滥用和药物成瘾的药物中的用途。
4.(4-(2-氟苯基)-6-甲基-2-(1-哌嗪基)噻吩并[2,3-D]嘧啶或其盐在制备用于鼓励吸烟停止的药物中的用途。
5.(4-(2-氟苯基)-6-甲基-2-(1-哌嗪基)噻吩并[2,3-D]嘧啶或其盐在制备用于治疗经前期综合征的药物中的用途。
6.(4-(2-氟苯基)-6-甲基-2-(1-哌嗪基)噻吩并[2,3-D]嘧啶或其盐在制备用于治疗进食障碍的药物中的用途。
7.(4-(2-氟苯基)-6-甲基-2-(1-哌嗪基)噻吩并[2,3-D]嘧啶或其盐在制备用于治疗偏头痛的药物中的用途。
8.(4-(2-氟苯基)-6-甲基-2-(1-哌嗪基)噻吩并[2,3-D]嘧啶或其盐在制备用于治疗帕金森氏病的药物中的用途。
9.(4-(2-氟苯基)-6-甲基-2-(1-哌嗪基)噻吩并[2,3-D]嘧啶或其盐在制备用于治疗中风的药物中的用途。
10.(4-(2-氟苯基)-6-甲基-2-(1-哌嗪基)噻吩并[2,3-D]嘧啶或其盐在制备用于治疗恶心和呕吐的药物中的用途。
11.(4-(2-氟苯基)-6-甲基-2-(1-哌嗪基)噻吩并[2,3-D]嘧啶或其盐在制备用于治疗化学疗法或放射性诱导的呕吐的药物中的用途。
12.(4-(2-氟苯基)-6-甲基-2-(1-哌嗪基)噻吩并[2,3-D]嘧啶或其盐在制备用于治疗精神分裂症的药物中的用途。
13.(4-(2-氟苯基)-6-甲基-2-(1-哌嗪基)噻吩并[2,3-D]嘧啶或其盐在制备用于治疗强迫观念与行为障碍的药物中的用途。
14.(4-(2-氟苯基)-6-甲基-2-(1-哌嗪基)噻吩并[2,3-D]嘧啶或其盐在制备用于治疗疲劳的药物中的用途。
15.根据权利要求1到14中任一项的用途,其中所述盐为盐酸盐一水化物。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0220064.0 | 2002-08-29 | ||
GB0220064A GB0220064D0 (en) | 2002-08-29 | 2002-08-29 | New therapeutic use |
GB0316115A GB0316115D0 (en) | 2003-07-09 | 2003-07-09 | New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno [2,3-d]pyrimidine |
GB0316115.5 | 2003-07-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1678322A true CN1678322A (zh) | 2005-10-05 |
Family
ID=31979994
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA03820617XA Pending CN1678322A (zh) | 2002-08-29 | 2003-08-28 | (4-(2-氟苯基)-6-甲基-2-(1-哌嗪基)噻吩并[2,3-d]嘧啶的新治疗用途 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20060167005A1 (zh) |
EP (1) | EP1539172A1 (zh) |
JP (1) | JP2006500427A (zh) |
KR (1) | KR20050058511A (zh) |
CN (1) | CN1678322A (zh) |
AU (1) | AU2003259373B2 (zh) |
BR (1) | BR0313836A (zh) |
CA (1) | CA2496695A1 (zh) |
WO (1) | WO2004019948A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040048874A1 (en) * | 2001-05-22 | 2004-03-11 | Bardsley Hazel Judith | New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine |
GB0216027D0 (en) | 2002-07-10 | 2002-08-21 | Arachnova Therapeutics Ltd | New therapeutic use |
NZ541009A (en) * | 2003-01-13 | 2007-09-28 | Dynogen Pharmaceuticals Inc | Method of treating nausea, vomiting, retching or any combination thereof |
EP1558081A4 (en) * | 2003-01-13 | 2006-06-14 | Dynogen Pharmaceuticals Inc | METHOD OF TREATING FUNCTIONAL INTESTINAL DISORDERS |
AU2004227945B2 (en) | 2003-04-04 | 2006-10-26 | Dynogen Pharmaceuticals, Inc. | Method of treating lower urinary tract disorders |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60146891A (ja) * | 1984-01-05 | 1985-08-02 | Mitsubishi Chem Ind Ltd | 〔2,3−d〕チエノピリミジン誘導体およびその塩 |
ZA958725B (en) * | 1994-10-20 | 1997-04-16 | Lilly Co Eli | Treatment of disorders with duloxetine |
US20020006964A1 (en) * | 1995-05-16 | 2002-01-17 | Young James W. | Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds |
ATE449603T1 (de) * | 1998-09-15 | 2009-12-15 | Lilly Co Eli | Verwendung von duloxetine zur behandlung von fibromyalgie |
US6673838B2 (en) * | 2001-02-12 | 2004-01-06 | Wyeth | Succinate salt of O-desmethyl-venlafaxine |
NZ541009A (en) * | 2003-01-13 | 2007-09-28 | Dynogen Pharmaceuticals Inc | Method of treating nausea, vomiting, retching or any combination thereof |
-
2003
- 2003-08-28 BR BR0313836-4A patent/BR0313836A/pt not_active IP Right Cessation
- 2003-08-28 WO PCT/GB2003/003720 patent/WO2004019948A1/en active Application Filing
- 2003-08-28 US US10/525,532 patent/US20060167005A1/en not_active Abandoned
- 2003-08-28 AU AU2003259373A patent/AU2003259373B2/en not_active Ceased
- 2003-08-28 KR KR1020057003158A patent/KR20050058511A/ko not_active Application Discontinuation
- 2003-08-28 CN CNA03820617XA patent/CN1678322A/zh active Pending
- 2003-08-28 JP JP2004569724A patent/JP2006500427A/ja active Pending
- 2003-08-28 EP EP03791032A patent/EP1539172A1/en not_active Withdrawn
- 2003-08-28 CA CA002496695A patent/CA2496695A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1539172A1 (en) | 2005-06-15 |
AU2003259373B2 (en) | 2006-03-09 |
US20060167005A1 (en) | 2006-07-27 |
BR0313836A (pt) | 2005-06-21 |
AU2003259373C1 (en) | 2004-03-19 |
JP2006500427A (ja) | 2006-01-05 |
WO2004019948A1 (en) | 2004-03-11 |
CA2496695A1 (en) | 2004-03-11 |
KR20050058511A (ko) | 2005-06-16 |
AU2003259373A1 (en) | 2004-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001019371A1 (en) | TREATMENT OF MOVEMENT DISORDERS BY ADMINISTRATION OF 5-HYDROXYTRYPTAMINE RECEPTOR/α2 ADRENERGIC RECEPTOR ANTAGONIST COMPOSITIONS | |
CN101646440A (zh) | 使用黄嘌呤氧化还原酶抑制剂和抗炎剂预防痛风突发或减少痛风突发次数的方法 | |
JPS61500665A (ja) | キサンチン類を含んでなる鎮痛および抗炎症組成物およびその使用法 | |
WO2006034631A1 (fr) | Composition comprenant de l’amlodipine et un antagoniste des recepteurs de l’angiotensine ii | |
WO2021248022A1 (en) | Methods of treating a coronavirus infection | |
KR20190049905A (ko) | 근위축성 측색경화증의 치료 또는 병세 진전 억제를 위한 약제 | |
CN1678322A (zh) | (4-(2-氟苯基)-6-甲基-2-(1-哌嗪基)噻吩并[2,3-d]嘧啶的新治疗用途 | |
US20090215791A1 (en) | New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-d]pyrimidine | |
WO1997021439A1 (fr) | Medicament destine au traitement des troubles obsessifs compulsifs, de l'apnee du sommeil, des dysfonctions sexuelles, de l'emese et du mal des transports | |
CN1279915C (zh) | 4-(2-氟苯基)-6-甲基-2-(1-哌嗪基)噻吩并(2,3-d)-嘧啶用于治疗尿失禁的用途 | |
CA2672273C (en) | Methods for the treatment of alcohol abuse, addiction and dependency | |
JP2003521469A (ja) | 睡眠時無呼吸症を治療する方法 | |
AU2003205836A1 (en) | Use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno(2, 3-d)-pyrimidine for treating of urinary incontinence | |
TWI289060B (en) | Pharmaceutical composition for improving the recovery of post-stroke patients | |
CN101189215A (zh) | 苯并氧氮辛因及其治疗用途 | |
JP2010536827A (ja) | ある種の炎症性障害の治療に有用なカルボニルアミノ誘導体 | |
CN1433306A (zh) | 用于治疗特发性震颤的抗惊厥衍生物 | |
WO2010098475A1 (ja) | 摂食障害予防及び治療剤 | |
WO2012058993A1 (zh) | 安倍生坦预防或减轻缺氧导致的心功能损伤的用途 | |
JP2898930B2 (ja) | 消化器症状改善剤 | |
JP2612417B2 (ja) | 消化器症状改善剤 | |
EP0267442B1 (en) | Tetrazolylquinazolinones as anti-hyperuricemic agents | |
WO2004016590A1 (fr) | Sels de derives de quinuclidine, elaboration et applications | |
CN117956959A (zh) | 用于治疗睡眠呼吸暂停的方法和组合物 | |
CN116688135A (zh) | 一种骨关节炎药物治疗组合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |